Roivant Sciences (ROIV) Gross Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) Gross Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 484.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 96.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -93.00 |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | -91.00 |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 210.00 |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 1,966.00 |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | -475.00 |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -553.00 |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -1,260.00 |
| 10 | Insmed | 28.20 Bn | 27.04 Bn | 358.27 Mn | 1,034.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,260.00 |
| Dec 31, 2025 | -1,353.00 |
| Sep 30, 2025 | -184.00 |
| Jun 30, 2025 | -443.00 |
| Dec 31, 2024 | 264.00 |
| Sep 30, 2024 | 88.00 |
| Jun 30, 2024 | 1,682.00 |
| Dec 31, 2023 | 2,049.00 |
| Sep 30, 2023 | 2,294.00 |
| Jun 30, 2023 | 2,048.00 |
| Dec 31, 2022 | -794.00 |
| Sep 30, 2022 | 1,657.00 |
| Jun 30, 2022 | -3,037.00 |
| Dec 31, 2021 | -657.00 |
| Sep 30, 2021 | 842.00 |
| Jun 30, 2021 | 183.00 |